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Summary Serum levels of mucin-like carcinoma associated antigen (MCA) were measured in 80 healthy
women, 109 patients with breast cancer at presentation and in samples taken from 45 patients with active
metastatic breast cancer. The MCA levels in controls had an upper limit of normal of 19.6Uml-1 in post-
menopausal and 16.4Uml- in premenopausal women. The levels at presentation in stages I and II and III
were not significantly different from the post-menopausal controls. Longitudinal studies over 5-9 years in 20
patients with stage I and II disease who had remained tumour-free showed a narrow MCA range for each
individual patient, but the mean and range of a single measurement in a further 63 of these patients were
similar to those of the normal controls. Rising MCA levels occurred in 12/14 patients who developed
metastases in 2-8 years after surgery, but local recurrence was not associated with a rise of MCA. Eighty
per cent of patients with active metastatic disease had MCA levels > 15 Uml-1. MCA levels fell during clinical
responses to therapy in metastatic cancer. In the context of follow-up serum MCA levels appear to be a
sensitive indicator of metastatic disease; caution is required in the interpretation of isolated measurements.
The search for tumour markers for the diagnosis, assessment
and follow-up of breast cancer has until recently been
disappointing. The long disease free interval that may occur
between the treatment of the primary tumour and its
eventual recurrence add particular difficulties when a marker
is to be used to assess prognosis and for the early
identification of recurrence. The criteria required for a
clinically useful marker have been reviewed by Waalkes et al.
(1984) and the limitations of analytes available at this time
summarised by Coombes et al. (1982). Carcinoembryonic
antigen (CEA), the most widely used cancer marker, has
been shown to be of value for monitoring the response to
treatment in about 60% of advanced metastatic breast
cancer but lacks the sensitivity and specificity to detect small
tumour burdens (Lamerz et al., 1979).
During the past 5 years the spectrum of breast cancer
markers has increased considerably as monoclonal antibody
(MAb) techniques have been applied to the problem. Several
MAb antibodies have been raised with highly selective
immunoreactivity against breast cancer cells which are
generally high molecular weight glycoproteins. MAb
immunoassays have been devised for the measurement of
several of these glycoproteins. The novel tests include
CA 15-3 (Hayes et al., 1986), mucin-like carcinoma
associated antigen (MCA) recognised by the antibody b-12
(Stahli et al., 1985, 1989; Bieglmayer et al., 1988), mammary
serum antigen (Sacks et al., 1987) and CA 549 (Gaur et al.,
1987; Chan et al., 1988). Recently a commercial two-step
enzyme-linked immunoassay (EIA) for MCA has become
available (Roche). We have used this assay to evaluate the
potential of MCA as a marker in breast cancer with
particular emphasis on the long-term monitoring of stage I
and II disease.
Materials and methods
Serum samples were collected from 40 healthy women <50
years old (premenopausal controls) and 40 women >50
years old (post-menopausal controls). The former were all
blood donors, the latter a mixture of blood donors and
patients attending the orthopaedic department.
Serum samples were obtained from patients with breast
cancer: (a) before surgery, (b) during follow-up, (c) with
recurrent or metastatic disease.
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This study was in the main retrospective, using banked
sera collected from a cohort of patients first seen between
1979 and 1984 with stage I and II disease. This part of the
investigation was designed to give information on the
variation of MCA levels in patients at risk of recurrence.
The remaining samples were accumulated from patients with
breast cancer attending hospital during the past 2 years; they
were selected as being representative of various stages and
clinical status.
Pretrcatmnent
Samples, taken before treatment, were obtained from 70
patients presenting with stage I and II tumours, 34 with
stage III and five with stage IV.
Follow-up
Tumour-free In 20 patients presenting with stage I or II
disease who have remained tumour-free for 5-9 years
consecutive yearly serum samples were analysed for their
MCA concentration. This set of patients was used to
illustrate the intra- and inter-patient variation of MCA level
during surveillance. The distribution of MCA levels was also
examined in the most recent follow-up sample from a further
63 patients who presented with stage I or II disease and had
remained tumour-free for 3-9 years. All serum samples were
stored at -20°C until use.
Recurrence
Serum samples were available from three patients with local
recurrence and 14 with metastatic disease from whom there
were antecedent serum samples available when they were
tumour-free. Further sera were obtained from 45 patients
with active metastatic disease who were not part of the long-
term follow up study. All serum samples were stored at
-20°C until use. Samples had been accumulated since 1979.
MCA assay The MCA-EIA (Roche Diagnostics, Welwyn
Garden City, Herts) was used according to the
manufacturer's instructions. The kit is a two-step solid phase
enzyme immunoassay. The assay employs the same
monoclonal mouse antibody to MCA (MAb b-12) in both
positions of the sandwich (as capture antibody and as
detection antibody), as this antibody recognises a repetitive
binding site on the MCA molecule. In a first step, the
patient's sera and MCA standards are incubated with MAb
coated beads. After a washing step, anti-MCA peroxidase
conjugate (anti-MCA antibody b-12 conjugated with
horseradish peroxidase) is added. After a second incubation
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step, unbound anti-MCA peroxidase conjugate is removed
by washing. Subsequently, the bead is incubated with
enzyme substrate and the extent of the resulting colour is
proportional to the amount of conjugate bound and hence to
the amount of MCA in the specimen. The patient and
control values are then determined by means of the standard
curve as described in the manufacturer's instructions;
the units of MCA were as defined by Stahli et al. (1989).
A control sample, with a designated mean vtlue
13Uml-1, provided by the manufacturer, was measured at
the beginning and end of each assay. The inter- and intra-
assay variation was also measured using a serum sample
with a value nearer the top of the measuring range.
Results
The control sample measured in quadruplicate gave a mean
value of 14.2Uml-1 measured on 10 runs with a coefficient
of variation (CV) of 5.2%. The higher serum control with a
mean value of 33.1 Uml1 had an inter-assay CV over five
runs of 9.6%, and an intra-assay CV of 8.5% (20 replicates).
The mean (±s.d.) MCA levels in female controls was
5.3 +4.7Uml - 1 in premenopausal women and
8.0 +4.9Uml-1 in post-menopausal women. There is a weak
correlation between MCA level and age (r=0.204). The
median and interquartile ranges for stage I and II combined,
stage III and the individual values for stage IV are shown in
Figure 1.
The effects of resection of the primary tumour on the
MCA level were examined in 18 patients with stage I and II
disease and two stage III by comparing their preoperative
levels with those 1-2 years later when tumour-free. The
paired t test showed no significant change (paired t=2.6138,
P=0.017).
Long-term follow-up
The levels of MCA measured annually in 20 patients who
have remained tumour-free are shown in Figure 2. This
shows the considerable between patient variation while the
intra-patient levels remain within relatively narrow limits.
The median level (and range) observed in the last available
serum from a further 63 patients who were tumour-free for
3-9 years was 7.4Uml-1 (1-21.1) confirming the wide
variance of the serum level of MCA in women who remain
at risk of recurrent or metastatic disease being nearly the
same as in healthy controls.
By contrast 12/14 patients who developed metastases 2-8
years after surgery and for whom serum samples were
available in the bank, had rising MCA levels. Ten of these
patients are illustrated in Figure 3. In three patients who
developed local recurrences there was no significant change
of MCA level between when they were tumour free and had
evidence of local recurrence.
Sera from a further 45 patients with active metastatic
breast cancer attending for treatment were examined to
determine the frequency of an elevated MCA level. Eighty
per cent of these patients had an MCA value of > 15Uml-1
and in 31% the value was > 100Uml-1. Longitudinal
studies were made for 4-8 months in 12 patients who were
receiving treatment for metastatic disease. Figure 4 illustrates
the fall in the MCA level following treatment in five
patients, another patient who was resistant to chemotherapy
had a level of 20-30Uml-1 sustained for 4 months. Changes
of MCA level within the normal range can occur on
treatment, in a patient with a level of 13 Uml-1 when
presenting with metastases, the response to chemotherapy
was associated with a sustained fall of MCA to <1 Uml- 1.
One patient who was initially considered to have bone
metastases but whose MCA level remained stable at less
than 10Uml-1 for several years had her diagnosis revised to
Padget's disease.
Discussion
Mucin-like carcinoma associated antigen has been identified
on the surface of mammary carcinoma cells by MAb b-12;
immunoblot studies showed it had a relative molecular
weight of 350,000 d (Stahli et al., 1985). This epitope is also
found in some normal mucinous epithelia including the distal
kidney tubules and ductules of the breast (Stahli et al.,
1985). MCA contains primarily 0-linked carbohydrate side
chains with sialic acid and hexoses including fucose (Stahli et
al., 1989).
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Figure 2 Levels of MCA in patients who have remained tumour-free after surgical treatment of their primary tumour. This
illustrates the median and range of levels in 20 individual patients, based on 5-9 annual measurements, as compared to the levels
in 63 additional patients, with a single data point when tumour-free, and 80 controls.
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MCA belongs to the group of mucin-like glycoproteins
(Stahli et al., 1989) released from breast cancers which
include the Ca antigen (Bramwell, 1983), CA 15-3 (Hayes et
al., 1986) and human milk fat globule membranes (Hilkens
et al., 1984; Turnbull et al., 1986).
While the inter-relationships of these glycoproteins are still
being elucidated (Stahli et al., 1989), MCA is sufficiently
interesting to warrant introduction as a commercially
available test for breast cancer and our study has provided
more clinical information about its performance.
The serum MCA levels in breast cancer at presentation
show considerable overlap with healthy controls; there is a
tendency for the levels to be higher in stage III with lymph
node involvement and in stage IV. A similar phenomenon
has been observed for CA 15-3 levels (Gion et al., 1986;
Pons-Anciet et al., 1987; Hayes et al., 1986). However, it is
evident that MCA lacks the sensitivity needed for it to be
used for population screening.
The variability of the latent period between primary breast
cancer and the detection of recurrence or metastases is a well
known characteristic of the disease. The use of stored
samples has demonstrated the behaviour of MCA in patients
who have remained tumour-free and in those who have
developed recurrence or distant metastases. The essential
feature is that each patient has his or her own level which
tends to be stable, as evidenced by repeated samples, over a
period of 5-9 years. The range is wide: < 1.0-21.0Uml-1. In
patients with MCA levels >11 Uml-1 as quoted by Roche
for the upper limit of normal, caution is needed in the
interpretation of a single observation, as some patients can
have apparent elevation of MCA for many years without
evidence of recurrence. However, during follow-up levels
>25Uml-1 were only seen in patients with metastatic
cancer.
As with several other tumour markers, such as CA 50 and
CA 15-3, there is considerable amplification of the level of
MCA in disseminated metastatic disease, with increases of
one to two orders of magnitude greater than the tumour-free
level (Hayes et al., 1986; Bieglmayer et al., 1988).
Browning et al. (1988) have compared MCA and CA 15-3
in controls and breast cancer. These two analytes are well
correlated (r=0.78) and would appear to give similar clinical
information, an observation confirmed by Bieglmayer et al.
(1988). Previous studies have shown that CA 15-3 is superior
to CEA in follow-up and for the monitoring of metastatic
breast cancer (Hayes et al., 1986; Pons-Anciet et al., 1987).
The present study suggests that MCA can provide a useful
marker for the follow-up of breast cancer patients. The
frequency of measurement will influence the lead time, in our
series the low risk patients were seen once a year. If the
detection of asymptomatic metastases is considered to be
advantageous then more frequent measurements of MCA
may be required.
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